周易生物
nordiabio.com/China (Hong Kong)
17 profile visits
About
Nordia targets on the diabetes with personal or universal islet organoids generated from stem cells through its spontaneous formation of 3D structure of islets. Gene editing and T cell co-culture were used to reduce the immunogenicity. The islet organoids will be transplanted into the patients with biomaterial scaffolds for long-term control of blood glucose levels by steady insulin secretion. Nordia also offers islet-based research services such as drug/target screening.
Areas of activity
Technology
Bio-TechMedical Technology
Urban Development
Technology Park
Additional information
Other Place of Business
Company Funding Stage
Terms and Conditions & Disclaimer
I agree
Representatives
生物医药早期项目孵化
周易生物
CTO
周易生物